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Abstract
Modern ebolavirus diagnostics rely primarily on quantitative reverse transcription-polymerase 
chain reaction (qRT-PCR), a sensitive method to detect viral genetic material in the acute phase of 
the disease. However, qRT-PCR does not confirm presence of infectious virus, presenting 
limitations in patient and outbreak management. Attempts to isolate infectious virus rely on in 
vivo or basic cell culture approaches, which prohibit rapid results and screening. In this study, we 
present a novel reporter cell line capable of detecting live ebolaviruses. These cells permit 
sensitive, large-scale screening and titration of infectious virus in experimental and clinical 
samples, independent of ebolavirus species and variant.
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Detecting ebolavirus ribonucleic acid (RNA) in patient samples by quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR) is a sensitive, first-line method readily 
adapted to the outbreak setting. However, a positive qRT-PCR result does not consistently 
equate to presence of infectious virus [1]. Moreover, minor differences in nucleotide 
sequence may render existing qRT-PCR assays unable to detect an emerging virus. 
Technically, qRT-PCR is easily scaled up and increasingly automated, whereas infectivity 
determination by virus isolation remains a more laborious task confined to biosafety level 4 
(BSL-4) laboratories. Our standard ebolavirus isolation protocol includes inoculation of 
Vero-E6 cells, with fixation and immunostaining of the cell monolayer on days 7 and 14 
postinfection; this procedure prohibits rapid results. In this work, we establish a reporter cell 
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line that produces a robust fluorescence signal in response to ebolavirus infection. We have 
validated this system using stocks of all 5 known virus species of the Ebolavirus genus, as 
well as virus-spiked human blood and serum samples and clinical samples from past 
outbreaks. Practical and scalable quantification of infectious Ebola virus and related viruses 
leaves us better prepared to conduct virus persistence studies and to detect emerging viruses 
in this important genus.
METHODS
Viruses and Biosafety
The following stock viruses were used in the study: Ebola virus/H. sapiens-tc/COD/1976/
Yambuku-Mayinga, Sudan virus/H.sapiens-tc/UGA/2000/Gulu-808892, Reston virus/
M.fascicularis-tc/USA/1989/Philippines89-Pennsylvania, Bundibugyo virus/H. sapiens-
tc/UGA/2007/Butalya-811250, Taï Forest virus/H.sapiens-tc/CIV/1994/Pauléoula-CI, and 
Marburg virus/R.aegyptiacus-tc/UGA/2007/Kitaka-371Bat-811277. All work with infectious 
virus was performed in a BSL-4 facility at the Centers for Disease Control and Prevention 
(CDC).
Reporter Cell Line
Gene synthesis (Integrated DNA Technologies, Coraville, IA) was used to generate a 
negative-sense minigenome that was initially assembled in the pcDNA5/FRT vector 
(Invitrogen, Waltham, MA) using InFusion HD cloning (Clontech, Mountain View, CA). 
The minigenome is driven by the constitutive cytomegalovirus (CMV) promoter and 
transcribed by host RNA polymerase II. The transcript contains a hammerhead ribozyme at 
the 5′ end to produce an exact RNA end mimicking that of Ebola virus Makona variant 
genome (GenBank sequence KP178538.1). The hammerhead ribozyme used here was 
modeled on the optimization work presented by Yun et al [2] and corresponds to the 
ribozyme A sequence presented there with the following modifications: stem I (which 
provides specificity) includes a 7-nucleotide complementarity with Ebola Makona trailer end 
(GGACACA), and the sequence upstream of this stem is from the vector. The minigenome 
transcript begins with the 176 base minimal promoter region as identified in defective-
interfering Ebola virus particles [3], followed by L messenger RNA (mRNA) untranslated 
region (UTR) between the polyadenylation signal and stop codon. The minimal promoter 
region ends in a U base, and the adjacent polyadenylation signal contains a 6 U stretch. The 
total number of U bases at the junction was left at 6. A codon-optimized sequence for 
zsGreen ([ZSG] Clontech) in negative sense orientation is followed by the Ebola Makona 
sequences preceding the nucleoprotein open reading frame, and the transcript 3′ end is 
trimmed by the “supercut” hepatitis delta virus ribozyme [4]. After initial optimization work 
(data not shown), the minigenome was transferred into the piggyBac transposon vector PB-
CMV-MCS-EF1-Puro (System Biosciences, Palo Alto, CA) using NheI and NotI restriction 
sites.
To generate stable cell lines, the resulting piggyBac construct was transfected into Vero-E6 
cells together with the Super piggy-Bac Transposase construct (System Biosciences) using 
TransIT LT1 reagent (Mirus Bio, Madison, WI) according to manufacturers’ instructions. 
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Three days after transfection, cells were trypsinized and seeded on cell culture dishes as a 
dilution series. Clones were selected and expanded under 30 μg/mL puromycin. Once 
enough cells were obtained, clones were ranked by minigenome activation after infection 
with Ebola virus, and the best-performing clones were expanded further. One such clone was 
chosen after additional experiments, and it was used here as the Vero-Ebola-reporter cell 
line. Characterization of the minigenome expression is presented in Supplementary Figure 1.
Sensitivity Assays
Aliquots of diluted virus stocks were repeatedly titered by 50% tissue culture infectious dose 
(TCID50) assays using 6 replicate wells of Vero-E6 cells and Vero-Ebola-reporter cells in 
parallel. Dilution series were prepared in medium containing 2% fetal calf serum, and 40 μL 
inoculum were used in each well of a 96-well plate. After 1-hour incubation at 37°C, the 
inocula were removed and medium without phenol red was added. The apparent titers on 
Vero-Ebola-reporter cells, as indicated by presence of ZSG-positive cells, were recorded on 
specified days postinfection until day 7, when the monolayers were fixed and 
immunostained using rabbit polyclonal antibodies detecting all known species of the genus 
Ebolavirus (in-house reagent 703371). Marburg virus was detected using rabbit polyclonal 
antibodies (reagent 703358). Quantification data of the ZSG signals upon infection are 
presented in Supplementary Figure 2.
To simulate low-titer clinical samples, healthy donor serum and ethylenediaminetetraacetic 
acid (EDTA) blood samples were spiked with stock viruses so that 95% of the mix was 
blood/serum. The spiked samples were aliquoted and frozen; a new vial was used for each 
repeat of the experiment. Spiked samples were inoculated neat and as dilution series in 
phosphate-buffered saline (PBS). The TCID50 assays were performed as described above, 
except that for blood samples, the cells were washed once with PBS after removing the 
inocula.
Clinical samples obtained during historical outbreak investigations were selected based on 
their known infectivity status. These samples were tested the same way as the spiked blood 
samples; however, due to limited sample volumes, 1:10 dilution in PBS was the lowest 
dilution inoculated, and the experiment was done only once. All storage conditions and 
number of freeze-thaw cycles from the place of collection to the laboratory could not be 
ascertained for the clinical samples, and the absolute infectivity values determined did not 
necessarily reflect the values of the same samples at time of collection. Centers for Disease 
Control and Prevention Institutional Review Board (IRB) approval was obtained for the use 
of historical diagnostic material; the IRB waived the requirement to obtain informed consent 
for this secondary use of archived samples. Healthy donor blood was obtained with informed 
consent under a separate IRB-approved research protocol.
RESULTS
Our reporter cell system uses an Ebola virus minigenome expression cassette (Figure 1A and 
Supplementary Figure 1) that was introduced into Vero-E6, our standard cell line for 
ebolavirus isolation, by a transposon system. Upon infection, the viral replication complex 
recognizes promoters on the minigenome RNA and uses it as template to transcribe mRNA 
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for the fluorescent protein, ZSG. Infectious virus can therefore be detected by monitoring 
ZSG fluorescence in live cells without additional reagents. As seen in Figure 1B, Ebola virus 
infection results in strong ZSG signals in a subset of infected Vero-Ebola-reporter cells, 
distinguishing infected from non-infected cultures. Importantly, infections with the other 
members of the Ebolavirus genus (Sudan, Bundibugyo, Reston, and Taï Forest viruses) also 
resulted in strong ZSG fluorescence, demonstrating that our system can detect multiple 
species of ebolaviruses with only minor differences in the activation potential (quantified in 
Supplementary Figure 2). The more distantly related filovirus, Marburg virus, could not 
activate the reporter.
Having established that infected Vero-Ebola-reporter cultures could be identified by the ZSG 
signal, we next evaluated the sensitivity of the system in comparison with virus detection by 
the standard immunofluorescence assay. We reasoned that titer determinations by the 
TCID50 method would serve this purpose. In this assay, replicate wells are infected with 10-
fold serial dilutions of the sample until no infectivity remains. Therefore, reduced sensitivity 
would manifest as failure to detect ZSG in the highest dilutions where live virus actually still 
exists, leading to reduced titer values. Apparent titers were determined daily by the reporter 
assay to assess the time required for reliable results. As shown in Figure 2A, all 5 
ebolaviruses could be quantified using the reporter cells. By day 7, titer values determined 
by ZSG reporter signal closely resembled the values obtained by immunofluorescence on 
Vero-E6 cells, indicating that the sensitivity of the Vero-Ebola-reporter system is similar to 
that of the standard assay.
Next, the system was tested with material relevant for diagnostics and virus discovery. In 
contrast to stock titration, detecting low levels of infectivity in clinical material may be 
hindered by exposure of cell monolayers to high concentrations of viscous original sample. 
For a stringent test, human EDTA blood and serum were spiked with Ebola or Sudan virus 
stocks to obtain 2 samples with infectivity values close to the TCID50 detection limit. As 
shown in Figure 2B, live Ebola or Sudan viruses in the 3–4 log/mL range could be 
reproducibly detected in blood by day 3, and <2-log/mL concentrations could be detected by 
day 4. Similar results were obtained with spiked serum samples. Mock-spiked control blood 
and serum samples tested negative in both TCID50 and Vero-Ebola-reporter cell line assays 
(data not shown).
Finally, actual clinical material was tested. Original samples known to contain live virus at 
unknown titers were selected; Ebola, Sudan, and Bundibugyo viruses, the 3 viruses known 
to cause major outbreaks in humans, were represented. All 3 viruses could be detected 
directly from clinical material (Figure 2C). Two samples (Ebola and Bundibugyo) at 
relatively high 5-log and 6-log/mL titers, respectively, could be judged positive by as early 
as 24 hours postinfection. One Sudan sample with 3-log/mL infectivity, as well as 2 samples 
(Ebola and Bundibugyo) with infectivity below the quantification limit, produced positive 
results in the Vero-Ebola-reporter system by day 3 postinfection. One Sudan sample was 
negative on Vero-E6 cells but positive on Vero-Ebola-reporter cells (1 of 6 wells on day 7).
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DISCUSSION
Molecular methods, such as qRT-PCR, have rightly become the first-line method to diagnose 
cases of Ebola virus disease. However, there is no substitute for culturing clinical samples in 
vitro or in vivo to determine presence of live virus and transmission risk. The rapid advances 
in the field of molecular diagnostics have not reached virus isolation, which remains largely 
manual work. Reporter cell systems have emerged to bridge the gap for some viruses, yet 
expanding the approach is not trivial; the technical principle used necessarily depends on the 
biology of the virus in question. Viruses whose genomes exist as deoxyribonucleic acid 
(DNA) in host nuclei, including herpesviruses and lentiviruses, have been detected after 
stable integration of plasmids with reporter genes under viral promoters [5, 6]. Infection 
activates transcription of the reporter gene from the DNA template. Reporter cell lines for 
RNA viruses must rely on alternative principles. Flaviviruses [7] and enteroviruses [8] have 
been detected by linking cleavage of specific peptide sequences by viral proteases with 
reporter activation. Influenza, a negative-strand RNA virus with a nuclear replication cycle, 
has been detected using the minigenome approach [9]. A stable minigenome cell line has 
also been developed for a positive-strand RNA virus with a cytoplasmic replication cycle 
[10].
In this study, we use the minigenome principle to cover viruses of genus Ebolavirus, which 
are negative-strand RNA viruses with a cytoplasmic replication cycle. This work was 
inspired by other groups that have previously reported on successful swapping of Ebola and 
Reston virus replication complexes and minigenomes, providing evidence that viruses within 
the genus Ebolavirus have conserved transcription and replication signals [11–13]. Some 
experimental systems have even indicated that this cross-activation extends to Marburg virus 
[12, 13], but in other systems [11, 14], as well as ours, such cross-activation was not 
observed. Indeed, our system detects all 5 known ebolaviruses in stock samples and all the 
tested ones in patient serum and blood. We consider cross-activation by multiple 
ebolaviruses advantageous, because detecting any type of ebolavirus, especially in clinical 
material, is arguably a situation of public health concern. Although the assay involves 
growing live ebolaviruses and is therefore confined to BSL-4 laboratories, it is easily 
scalable and simple to perform, considerably increasing the capacity to detect infectious 
virus. We intend to use the cell line in projects involving ecological and clinical samples 
potentially containing live Ebola virus and its relatives, those known to date, and those that 
may yet be discovered.
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Figure 1. 
Ebola virus minigenome schematic and reporter cell activation by different filoviruses. (A) 
Schematic presentation of Ebola virus genome and the minigenome cassette. (B) Activation 
of zsGreen (ZSG) reporter upon infection. Vero-E6 cells and Vero-Ebola-reporter cells were 
infected at multiplicity of infection = 0.5 and immunostained 3 days postinfection. 
Abbreviations: CMV prom., cytomegalovirus promoter; GPC, glycoprotein precursor; 
HDVRz, hepatitis delta virus ribozyme; HHRz, hammerhead ribozyme; L, ribonucleic acid 
(RNA)-dependent-RNA-polymerase; NP, nucleoprotein; UTR, untranslated region; VP, viral 
protein; ZSG, zsGreen; α-Virus, immunostaining against the virus with specific antibodies.
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Figure 2. 
Quantifying infectious virus with the reporter cell line. All inserts represent virus titer values 
as 50% tissue culture infectious dose (TCID)50/mL. (A) Stock virus titration. (B) 
Ethylenediaminetetraacetic acid blood and serum samples spiked with Ebola or Sudan 
viruses at 2 concentrations. (C) Clinical samples. Green bars represent titers determined by 
zsGreen (ZSG) signal. Orange and red bars represent titers determined by immunostaining 
on Vero-Ebola-reporter cells and Vero-E6 cells, respectively. Day postinfection is depicted 
by numbers, and positive (all repeats) or negative results are depicted by +/− symbols. 
Dashed horizontal lines indicate TCID50 quantification limit. Open bars below 
quantification limit represent time points at which live virus was detected in all repeat 
experiments, but at least 1 repeat did not produce enough signal for TCID50 calculation. A 
and B represent averages and standard deviations from 3 independent experiments. C 
presents a single experiment. Abbreviation: DRC, Democratic Republic of the Congo.
Kainulainen et al. Page 8
J Infect Dis. Author manuscript; available in PMC 2018 December 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
